PMC:7172841 / 1088-1386 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T12","span":{"begin":87,"end":90},"obj":"Body_part"},{"id":"T13","span":{"begin":148,"end":156},"obj":"Body_part"},{"id":"T14","span":{"begin":284,"end":294},"obj":"Body_part"}],"attributes":[{"id":"A12","pred":"fma_id","subj":"T12","obj":"http://purl.org/sig/ont/fma/fma84795"},{"id":"A13","pred":"fma_id","subj":"T13","obj":"http://purl.org/sig/ont/fma/fma84050"},{"id":"A14","pred":"fma_id","subj":"T14","obj":"http://purl.org/sig/ont/fma/fma63261"}],"text":"ttern of immune dysregulation in severe COVID-19 is characterized by IL-6-mediated low HLA-DR expression and lymphopenia, associated with sustained cytokine production and hyper-inflammation.\n\nGraphical Abstract\n\nHighlights\n• Severe COVID-19 patients display immune dysregulation or macrophage act"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T15","span":{"begin":40,"end":48},"obj":"Disease"},{"id":"T16","span":{"begin":109,"end":120},"obj":"Disease"},{"id":"T17","span":{"begin":178,"end":190},"obj":"Disease"},{"id":"T18","span":{"begin":234,"end":242},"obj":"Disease"}],"attributes":[{"id":"A15","pred":"mondo_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A16","pred":"mondo_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/MONDO_0003783"},{"id":"A17","pred":"mondo_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/MONDO_0021166"},{"id":"A18","pred":"mondo_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"ttern of immune dysregulation in severe COVID-19 is characterized by IL-6-mediated low HLA-DR expression and lymphopenia, associated with sustained cytokine production and hyper-inflammation.\n\nGraphical Abstract\n\nHighlights\n• Severe COVID-19 patients display immune dysregulation or macrophage act"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T9","span":{"begin":69,"end":71},"obj":"Chemical"},{"id":"T11","span":{"begin":91,"end":93},"obj":"Chemical"}],"attributes":[{"id":"A9","pred":"chebi_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A10","pred":"chebi_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A11","pred":"chebi_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/CHEBI_73445"}],"text":"ttern of immune dysregulation in severe COVID-19 is characterized by IL-6-mediated low HLA-DR expression and lymphopenia, associated with sustained cytokine production and hyper-inflammation.\n\nGraphical Abstract\n\nHighlights\n• Severe COVID-19 patients display immune dysregulation or macrophage act"}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T9","span":{"begin":148,"end":167},"obj":"http://purl.obolibrary.org/obo/GO_0001816"},{"id":"T10","span":{"begin":178,"end":190},"obj":"http://purl.obolibrary.org/obo/GO_0006954"}],"text":"ttern of immune dysregulation in severe COVID-19 is characterized by IL-6-mediated low HLA-DR expression and lymphopenia, associated with sustained cytokine production and hyper-inflammation.\n\nGraphical Abstract\n\nHighlights\n• Severe COVID-19 patients display immune dysregulation or macrophage act"}

{"project":"LitCovid-sentences","denotations":[{"id":"T11","span":{"begin":193,"end":211},"obj":"Sentence"},{"id":"T12","span":{"begin":213,"end":223},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"ttern of immune dysregulation in severe COVID-19 is characterized by IL-6-mediated low HLA-DR expression and lymphopenia, associated with sustained cytokine production and hyper-inflammation.\n\nGraphical Abstract\n\nHighlights\n• Severe COVID-19 patients display immune dysregulation or macrophage act"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T6","span":{"begin":9,"end":29},"obj":"Phenotype"},{"id":"T7","span":{"begin":109,"end":120},"obj":"Phenotype"},{"id":"T8","span":{"begin":260,"end":280},"obj":"Phenotype"}],"attributes":[{"id":"A6","pred":"hp_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/HP_0002958"},{"id":"A7","pred":"hp_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/HP_0001888"},{"id":"A8","pred":"hp_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/HP_0002958"}],"text":"ttern of immune dysregulation in severe COVID-19 is characterized by IL-6-mediated low HLA-DR expression and lymphopenia, associated with sustained cytokine production and hyper-inflammation.\n\nGraphical Abstract\n\nHighlights\n• Severe COVID-19 patients display immune dysregulation or macrophage act"}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T38","span":{"begin":9,"end":15},"obj":"UBERON:0002405"},{"id":"T39","span":{"begin":16,"end":29},"obj":"GO:0065007"},{"id":"T40","span":{"begin":40,"end":48},"obj":"SP_7"},{"id":"T41","span":{"begin":69,"end":73},"obj":"PR:000001393"},{"id":"T42","span":{"begin":87,"end":90},"obj":"PR:000029150"},{"id":"T43","span":{"begin":94,"end":104},"obj":"GO:0010467"},{"id":"T44","span":{"begin":234,"end":242},"obj":"SP_7"},{"id":"T45","span":{"begin":260,"end":266},"obj":"UBERON:0002405"},{"id":"T46","span":{"begin":267,"end":280},"obj":"GO:0065007"},{"id":"T47","span":{"begin":284,"end":294},"obj":"CL:0000235;GO:0042116"},{"id":"T2958","span":{"begin":9,"end":15},"obj":"UBERON:0002405"},{"id":"T86620","span":{"begin":16,"end":29},"obj":"GO:0065007"},{"id":"T3195","span":{"begin":40,"end":48},"obj":"SP_7"},{"id":"T88472","span":{"begin":69,"end":73},"obj":"PR:000001393"},{"id":"T6458","span":{"begin":87,"end":90},"obj":"PR:000029150"},{"id":"T72315","span":{"begin":94,"end":104},"obj":"GO:0010467"},{"id":"T19296","span":{"begin":234,"end":242},"obj":"SP_7"},{"id":"T3907","span":{"begin":260,"end":266},"obj":"UBERON:0002405"},{"id":"T65562","span":{"begin":267,"end":280},"obj":"GO:0065007"},{"id":"T99154","span":{"begin":284,"end":294},"obj":"CL:0000235;GO:0042116"}],"text":"ttern of immune dysregulation in severe COVID-19 is characterized by IL-6-mediated low HLA-DR expression and lymphopenia, associated with sustained cytokine production and hyper-inflammation.\n\nGraphical Abstract\n\nHighlights\n• Severe COVID-19 patients display immune dysregulation or macrophage act"}

{"project":"LitCovid-PubTator","denotations":[{"id":"43","span":{"begin":69,"end":73},"obj":"Gene"},{"id":"63","span":{"begin":40,"end":48},"obj":"Disease"},{"id":"64","span":{"begin":109,"end":120},"obj":"Disease"},{"id":"65","span":{"begin":172,"end":190},"obj":"Disease"},{"id":"69","span":{"begin":243,"end":251},"obj":"Species"},{"id":"70","span":{"begin":234,"end":242},"obj":"Disease"}],"attributes":[{"id":"A43","pred":"tao:has_database_id","subj":"43","obj":"Gene:3569"},{"id":"A63","pred":"tao:has_database_id","subj":"63","obj":"MESH:C000657245"},{"id":"A64","pred":"tao:has_database_id","subj":"64","obj":"MESH:D008231"},{"id":"A65","pred":"tao:has_database_id","subj":"65","obj":"MESH:D007249"},{"id":"A69","pred":"tao:has_database_id","subj":"69","obj":"Tax:9606"},{"id":"A70","pred":"tao:has_database_id","subj":"70","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"ttern of immune dysregulation in severe COVID-19 is characterized by IL-6-mediated low HLA-DR expression and lymphopenia, associated with sustained cytokine production and hyper-inflammation.\n\nGraphical Abstract\n\nHighlights\n• Severe COVID-19 patients display immune dysregulation or macrophage act"}